Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent
- PMID: 17937416
- DOI: 10.1002/jbm.a.31664
Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent
Abstract
Drug-eluting stents have proven superior to bare metal stents with lower restenosis rates. Local delivery of drugs from these stents is achieved in most cases with the help of biostable polymer coatings. However, since the polymer coating remains in the body well after all the drug is released, patients can potentially develop hypersensitivity to these polymers--leading to complications such as late-stent thrombosis. It is therefore important that the polymers are designed to be biocompatible and well tolerated by the body. The polymer coatings are also expected to be robust and provide good control over elution of the desired drug. This paper describes the development of a unique, proprietary polymer blend system, specially designed to meet these requirements. Mutually compatible, free-radical-initiated elastomeric polymers were designed to provide a robust coating and offer a steady, sustained release of the highly hydrophobic drug zotarolimus over an extended period. The polymer blend system is also well tolerated by the hydrophilic environment in vivo, as demonstrated through porcine studies.
Similar articles
-
Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating.Catheter Cardiovasc Interv. 2008 Aug 1;72(2):186-94. doi: 10.1002/ccd.21607. Catheter Cardiovasc Interv. 2008. PMID: 18651646
-
In vitro and in vivo performance of a dual drug-eluting stent (DDES).Biomaterials. 2010 May;31(15):4382-91. doi: 10.1016/j.biomaterials.2010.01.147. Epub 2010 Feb 26. Biomaterials. 2010. PMID: 20189244
-
Polymer coatings and delayed arterial healing following drug-eluting stent implantation.Minerva Cardioangiol. 2009 Oct;57(5):567-84. Minerva Cardioangiol. 2009. PMID: 19838148 Review.
-
The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts.Biomaterials. 2009 Feb;30(4):632-7. doi: 10.1016/j.biomaterials.2008.10.005. Epub 2008 Nov 5. Biomaterials. 2009. PMID: 18990438
-
Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents.Bioconjug Chem. 2015 Jul 15;26(7):1277-88. doi: 10.1021/acs.bioconjchem.5b00192. Epub 2015 Jun 18. Bioconjug Chem. 2015. PMID: 26041505 Review.
Cited by
-
Temporal Trends in the Outcomes of Percutaneous Coronary Intervention With Zotarolimus Eluting Stents Versus Everolimus Eluting Stents: A Meta-Analysis of Randomized Controlled Trials.Clin Cardiol. 2024 Jun;47(6):e24306. doi: 10.1002/clc.24306. Clin Cardiol. 2024. PMID: 38888152 Free PMC article.
-
Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial.Eur Heart J. 2011 Oct;32(19):2454-63. doi: 10.1093/eurheartj/ehr182. Epub 2011 Jun 9. Eur Heart J. 2011. PMID: 21659439 Free PMC article. Clinical Trial.
-
Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study.Postepy Kardiol Interwencyjnej. 2019;15(2):143-150. doi: 10.5114/aic.2019.86009. Epub 2019 Jun 26. Postepy Kardiol Interwencyjnej. 2019. PMID: 31497046 Free PMC article.
-
Bacterial colonization of bone allografts: establishment and effects of antibiotics.Clin Orthop Relat Res. 2010 Aug;468(8):2113-21. doi: 10.1007/s11999-010-1322-8. Clin Orthop Relat Res. 2010. PMID: 20361282 Free PMC article.
-
Durable Polymer Drug Eluting Stent-Induced Kounis Syndrome and Eosinophilia Requiring Long-term Immunosuppression.Can J Cardiol. 2022 Mar;38(3):398-400. doi: 10.1016/j.cjca.2021.12.001. Epub 2021 Dec 10. Can J Cardiol. 2022. PMID: 34902455 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources